Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Budesonide Suspension in Eosinophilic Esophagitis
NCT01642212Phase 2Completed
- Sponsor
- Takeda
- Start
- Jul 2012
- Primary completion
- Oct 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of EPI-EE in eosinophilic esophagitis (EoE), sponsored by Takeda. Primary endpoint: Percent of Participants Who Were Histologic Responders at 16 weeks. Started Jul 2012; status: completed.
02
Drugs
EPI-EE
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT01642212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01642212.